Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/30—Oestrogens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/32—Antioestrogens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to a combination preparation comprising an ERß-specific agonist and an antiestrogen or SERM, preferably an ER ⁇ -selective antiestrogen, in particular a peripheral selective ER ⁇ -selective antiestrogen or / and an ER ⁇ -selective SERM.
• an antiestrogen or SERM preferably an ER ⁇ -selective antiestrogen, in particular a peripheral selective ER ⁇ -selective antiestrogen or / and an ER ⁇ -selective SERM.
• estrogens to treat hormone deficiency-related symptoms such as hot flashes and atrophy of estrogen target organs, as well as to prevent bone loss in peri- and postmenopausal women, has been well documented and generally accepted. It is also well documented that estrogen replacement therapy in postmenopausal women or in women with other-related ovarian dysfunction reduces the risk of cardiovascular diseases compared to women who have not been treated with estrogen (Grady et al. (1 992), Ann Intern Med 1 17, 101 6-1037 ).
• estrogens have a protective effect against neurodegenerative diseases, e.g. Alzheimer's disease (Henderson (1 997), Neurology 48 (Suppl 7), S27-S35; Birge (1 997), Neurology 48 (Suppl 7), S36-S41), has a protective effect on brain functions such as memory and learning ability (McEwen et al. (1 997), Neurology 48 (Suppl 7), S8-S1 5; Sherwin (1997), Neurology 48 (Suppl 7), S21 -S26), as well as against mood fluctuations due to hormone deficiency (Halbreich (1 997), Neurology 48 (Suppl 7), S1 6- S20).
• classic estrogens such as estradiol and conjugated estrogens from horse urns are used either alone or in combination with a gestagen.
• estrogen / progestogen combination preparations are predominantly used in hormone replacement therapy.
• the estrogen / progestogen combination avoids endometrial hypertrophy, but the combination is also linked to the occurrence of unwanted intermenstrual bleeding.
• estrogen / progestogen combination preparations are selective estrogens, substances that have an estrogen-like effect on the brain, bones and vascular system, but not proliferatively on the endometrium.
• SERM Selective Estrogen Receptor Modulators
• Estrogens exert their physiological effect via a receptor protein, the estrogen receptor (ER). It is a core transcription factor that can be activated by ligands. Until a few years ago, estrogens were thought to exert their effect through a single receptor. Recently, however, ERß was the second subtype of Estrogen receptor discovered (Kuiper et al. (1 996), Proc. Natl. Acad. Sci. 93, 5925-5930; Mosselman, Dijkema (1 996), Febs Letters 392, 49-53; Tremblay et al. (1 997) , Molecular Endocrinology 1 1, 353-365). The expression pattern of ERß differs from that of ER ⁇ (Kuiper et al.
• ERß predominates over ER ⁇ in the rat prostate (Chang, Prins (1999), The Prostate 40, 1 15-124), while ER ⁇ predominates in rat uterus. Areas were identified in the brain in which only one of the two ER subtypes is expressed (Shugrue et al. (1 996), Steroids 61, 678-681; Li et al. (1 997), Neuroendocrinology 66, 63-67 ). ERß is expressed, inter alia, in areas which are assigned importance for cognitive processes and 'mood' (Shugrue et al. (1 997), J. Comparative Neurology 388, 507-525).
• ER ⁇ is predominantly found in the liver, kidney and pituitary gland (Shugrue et al. (1 998), Steroids 63,
• ER ⁇ dominates in the uterus (Wang et al. (1 999), Biol. Of
• the ERs act as ligand-activated transcription factors. Receptor dimerization occurs after the hormone has bound. Depending on the expression of ER ⁇ and / or ERß in a cell, a homodimer or heterodimer ERo * and ERß forms (Cowley et al. (1997), J. Biol. Chem. 272, 1 9858-1 9862).
• the dimer binds to a specific one Sequence in the promoter of a target gene, the 'estrogen response element' ERE (Kumar, Chambon (1 988), Cell 55, 145-1 56; Klein-Hitpass et al. (1 986), Cell 46, 1053-1061). Binding of the receptor dimer to the ERE results in the recruitment of essential transcription factors and the initiation of transcription.
• ERß acts as a repressor for ER-stimulated transactivation (Hall, McDonnell (1 999), Endocrinology 1 40, 5566-5578).
• This function of ERß as a modulator of ER ⁇ with regard to transactivation is attributed to the fact that the response to estrogen administration in the uterus is more pronounced in ERß knock-out mice than in wild-type mice (Gustafsson, Steamboat Springs (February 2000), oral communication).
• IL-6 is regarded as the central mediator of immune and inflammatory reactions, as well as of osteoclastogenesis (Sehgal (1 992), Res. Immunol., 724-734; Jones (1994), Clin. Endocrinol. 40, 703-71 3).
• Estrogens suppress IL-6 production through osteoblasts and bone marrow stromal cells.
• IL-6 stimulates osteoclast recruitment and maturation
• estrogens inhibit this process by inhibiting IL-6 production.
• This inhibition of IL-6 production occurs by inhibiting the expression of IL-6 gene (Pottratz et al. (1 993), J. Clin. Invest. 93, 944-950; Stein, Young (1 995), Mol. Cell Biol. 1 5, 4971-4979).
• the ER-mediated inhibitory effect of the estrogens is brought about by inhibiting the activity of the transcription factor NF / cb. This transcription factor is activated by inflammatory signals (Thanos, Maniatis (1 995), Cell 80, 529-532; Didonato et al. (1 997), Nature 388, 548-554).
• IL-6 reporter gene assay was developed by Pottratz et al. (1,993), supra.
• the ligand-activated ER inhibited the activity of a reporter gene in various cell lines which contained the NF / do binding site of the IL-6 gene in the promoter (Pottratz et al. (1 993), J. Clin. Invest. 93, 944-950) ,
• a disadvantage of previous estrogen therapies is often the poor organ selectivity.
• the object on which the present invention is based was to develop preparations for estrogen therapy in which the disadvantages of the prior art are at least partially eliminated.
• organ-selective estrogen therapy is possible by administering a combination preparation comprising one for ERß-selective agonists and an antiestrogen or a selective estrogen receptor modulator (SERM).
• the combination preparation is suitable for the therapy or prophylaxis of estrogen deficiency-related diseases.
• the two components of the preparation can be administered in a common administration form (for example a preparation with two components) or in separate administration forms (two preparations with one component each).
• the combination preparation according to the invention is excellently suitable for organ-selective estrogen therapy and has a clear superiority over existing therapies.
• an ant ⁇ -selective antagonist in particular a peripheral-selective ERcr-selective antagonist, is used as the antiestrogen.
• an ERor-selective SERM is used.
• the drug achieves an at least largely complete estrogenic effect on organ systems or tissues such as the bones, the vascular system, brain functions and components of the immune system, while no or only marginal estrogenic effects on organ systems such as the uterus, liver, mammary gland and pituitary gland.
• the new drug is superior to conventional estrogen or hormone replacement therapy with estrogens or estrogen / progestogen combinations due to its reduced effect on the uterus and the prevention of bleeding.
• the drug is superior in its protection against estrogen-deficient bone mass loss.
• the drug described here is superior due to an improved "therapeutic window" (clear dissociation between bone-protective and uterus-stimulating dosages).
• the special combination of the ERß-selective estrogen with the ER ⁇ -selective antiestrogen or SERM ensures that in cells and organ systems that exclusively or predominantly express ERß, such as the brain, ERß-dependent estrogen effects are induced by the ERß-selective estrogen component of the preparation become.
• ERß-selective SERM or antiestrogen and the ERß agonist act antiproliferatively in the same direction.
• organs such as the bone in which both ER ⁇ and ERß are expressed, the ER ⁇ -selective SERM or antiestrogen and the ERß estrogen have an additive effect on protection against estrogen-deficient bone mass loss.
• antiproliferative and anti-inflammatory effects are exerted by the ER ⁇ -selective SERM or antiestrogen and the ERß agonist in the vascular system and thus have a synergistic effect on protection against vascular diseases such as atherosclerosis.
• the invention relates to a combination preparation, its production, therapeutic use and pharmaceutical dosage forms, consisting of a novel selective estrogen, an ERß-selective estrogen and an antiestrogen, preferably a so-called SERM (SR Kauffman, HU Bryant (1995), DN @ P 8 (9), 531-539).
• SERM SR Kauffman, HU Bryant (1995), DN @ P 8 (9), 531-539.
• SERM SR Kauffman, HU Bryant (1995), DN @ P 8 (9), 531-539.
• SERM SR Kauffman, HU Bryant (1995), DN @ P 8 (9), 531-539
• an ERß-selective estrogen with a SERM or with an antiestrogen which has higher affinity for the rat uterus receptor, in comparison to the rat prostate receptor or for ER ⁇ in comparison to ERß, in particular those compounds which are peripherally selective, ie which act as the blood-brain barrier not happen.
• Raloxifene (Barkhelm et al. (1998), Mol. Pharmacol. 54, 105-112), which is claimed for the present application.
• peripheral selective antiestrogens are ZM 182780, 11 ⁇ -fluoro-7 ⁇ - (14, 14, 15, 15, 15-pentafluoro-6-methyl-10-thia-6-azapentadecyl) estra-1,3,5 (10 ) -triene-3,17ß-diol and other 7 ⁇ -alkyl estratrienes (PCT / EP97 / 045517) and 11 ß-fluoro-7 ⁇ - (13, 13, 14, 14, 15, 15, 16, 16, 16- nonaf luoro-6-methyl-6-azahexadecyl) estra-1,3,5 (10) -triene-3,17 ⁇ -diol.
• peripheral selective SERM is 5- (4- ⁇ 5 - [(RS) - (4,4,5,5,5-pentafluoropentyl) sulfinyl] pentyloxy ⁇ phenyl) -6-phenyl-8,9-dihydro- 7H-benzocyclohepten-2-ol.
• Peripheral selective antiestrogens and SERMs can be part of the described here Medication and are claimed for this application.
• SERMs such as 1 4 ⁇ , 1 7 a - E thano - 1 1 ß - ⁇ 4 - [5 - (2 - pyridinmethylsuifonyl) pentyloxy] phenyl ⁇ -1, 3.5 (1 0) estratrien-3, 1 7ß -diol (1 1 ß-substituted steoids), TSE 424 and other 2-phenylindoles (American Home), EM 652, EM 800, CP 3361 56 (Lasofoxifene, Pfizer; Hua et al. (2000), Endocrinology 141, 1338- 1 344) can be part of the combination preparation and are claimed for this application.
• An ERß-selective estrogen as a component of the combination preparation which is the subject of this invention is characterized by higher affinity for the estrogen receptor of rat prostate compared to rat uterus, or by higher affinity for ERß compared to ER ⁇ . This includes
• Estrogens which have been described in various patent applications, as a possible component of the combination preparation: e.g. a) ASTRA, Novel
• the ERß agonist is preferably selected from 3, 1 6-Dihydroxyestra-1, 3.5 (10) -triene derivatives, 8 ⁇ -H, 9ß-H, 10 ⁇ -H, 13 ⁇ -H, 14ß-H-gonane derivatives, preferably derived of ent-1 3-alkylgonane, 8 ⁇ -substituted estra-1,3,5 (10) -triene derivatives and gona-1,3,5 (10) -triene derivatives.
• Examples of particularly preferred ER ⁇ antagonists are described in PCT / EPOO / 01073, DE 1 99 1 7 930.1, DE 1 99 41 105.1 and DE 100 19 1 67.3.
• a selective estrogen effect of the preparation according to the invention can be achieved due to the different tissue distribution of ER ⁇ and ERß by subtype-specific ligands.
• Substances with preference for ERß compared to ER ⁇ in the in vitro receptor binding test were described by Kuiper et al. (Kuiper et al. (1 996), Endocrinology 1 38, 863-870).
• ERß selectivity includes the phytoestrogen genistein and the DHEA metabolite androstenediol.
• ERß-selective estrogens have been described in various patents: ERß-affine ent steroids; 1 6-OH steroids; Nor-steroids; 8-ß-substituted steroids.
• the present application claims further selective estrogens and prodrugs, which have been described in various patent applications, as possible components of the preparation: a) ASTRA, Novel Estrogens, WO97 / 081 88, 9502921-1, PCT / SE96 / 01028; b) Sumitomo Chemical Co.
• the combination preparation according to the invention is particularly suitable for tissue- or organ-selective estrogen therapy; for example for the prophylaxis or treatment of peri- and postmenopausal complaints, for hormone substitution, for the prophylaxis or treatment of symptoms related to hormone deficiency, in particular for ovarian dysfunction, for the prophylaxis and treatment of hormone deficiency-related bone loss and osteoporosis, for the prophylaxis and treatment of cardiovascular and vascular diseases for the prophylaxis and treatment of hormone deficiency-related and neurodegenerative diseases, for the prophylaxis and treatment of hormone deficiency-related impairments of memory and learning ability and for the prophylaxis and treatment of diseases of the immune system.
• the new drug is particularly suitable for the treatment of peri- and postmenopausal complaints, in particular hot flashes, sleep disorders, irritability, mood swings, incontinence, vaginal atrophy and hormone deficiency-related mood disorders.
• the preparation is also suitable for hormone replacement and the therapy of hormone deficiency-related complaints in the case of surgical, medicinal or other-related ovarian dysfunction.
• the preparation is also used for the prophylaxis of hormone deficiency-related bone mass loss and osteoporosis, for the prevention of cardiovascular diseases, especially vascular diseases such as atherosclerosis and for the prevention of hormone deficiency-related neurodegenerative diseases such as Alzheimer's disease and hormone deficiency-related impairment of memory and learning ability.
• the preparation can also be used to treat inflammatory diseases of the immune system, in particular autoimmune diseases, such as rheumatoid arthritis.
• autoimmune diseases such as rheumatoid arthritis.
• the drug is suitable for the therapy and prophylaxis of estrogen deficiency-related diseases of both women and men.
• the drug is particularly suitable in men for the therapy of hormone deficiency-related bone mass loss and osteoporosis, for the prevention of cardiovascular diseases, in particular vascular diseases such as atherosclerosis and for the prevention of hormone deficiency-related neurodegenerative diseases such as Alzheimer's disease as well as hormone deficiency-related impairment of the memory and prognostic ability and learning ability.
• the drug is used to treat inflammatory and immune system diseases, especially autoimmune diseases such as Rheumatoid arthritis, can be used.
• ERß is able to inhibit NF / cb-controlled reporter genes.
• the SERMs prove to be partial antagonists if they exert their effect via ER ⁇ , ie they inhibit reporter gene activity in an estrogen-like manner and exert an antagonistic (in the sense of an actively transrepressing) effect in the presence of Estradiol from ( Figure 1). This effect is reflected in vivo by an antiresorptive (bone protective) effect.
• SERMs act via ERß, they have no agonistic effect on an NF b-controlled reporter gene ( Figure 2).
• the additive effect on inhibition of the NF / b-controlled promoter of SERM and ERß-selective estrogen in cultured cells which express ER ⁇ and ERß implies an additive antiresorptive (bone-protective) effect in vivo, since bone cells are both ER ⁇ and also in the intact organism also express ERß. Furthermore, it can be concluded that the combination of ERß-specific estrogen and SERM in vivo has an additive or synergistic effect on inhibiting inflammation-induced genes if the cells of the target organ express both ER ⁇ and ERß. This applies e.g. for the cardiovascular system.
• SERMs in particular ER ⁇ -selective SERMs, allow selective estrogen therapy insofar as they inhibit estrogen deficiency-induced bone loss and thereby cause little or no stimulation of uterine growth.
• Their bone protective (antiresorptive) effect is based on the inhibition of the expression of osteoclast-stimulating cytokines. They exert this effect via ER ⁇ in bone cells (inhibition of NF / cb).
• SERMs act as antiestrogens on the uterus; they inhibit estrogen-stimulated growth of the uterus, especially the proliferation of the ephitel. You exercise this effect through ER ⁇ .
• SERMs also exert anti-estrogen and anti-proliferation effects on breast cancer cells.
• the amounts of components (a) and (b) of the pharmaceutical combination preparation according to the invention to be administered can be all amounts with which the desired effect is achieved.
• the amount of component (a) to be administered is preferably 0.01 / g / kg to 10 mg / kg body weight, particularly preferably 0.04 ⁇ g / kg to 1 mg / kg body weight per day.
• the amount of component (b) to be administered is preferably 0.01 / g / kg to 10 mg / kg body weight, particularly preferably from 0.04 / g / kg to 1 mg / kg body weight per day.
• a dose unit of the pharmaceutical combination preparation according to the invention preferably contains 0.8 ⁇ g to 800 mg, preferably 1.6 / g to 200 mg, of each of components (a) and (b).
• the ratio of the two components (a) and (b) in the combination preparation according to the invention can vary over a wide range and is preferably 1:99 to 99: 1 by weight, particularly preferably 10:90 to 90: 10 by weight.
• Components (a) and (b) can be administered simultaneously or in succession. In particular, it is possible to alternately administer the active ingredients in succession. Suitable administration protocols are, for example, subcutaneous administration or oral administration.
• the active compounds can be administered several times a day, for example one to 10 times a day and over a number of days, for example over a period of 1 to 60 days, preferably from 1 to 30 days.
• the pharmaceutical combination preparations contain the active substances, if appropriate in a mixture with pharmacologically customary carriers, auxiliaries or diluents and, if appropriate, with other pharmacologically or pharmaceutically active substances, such as gestagens.
• the pharmaceuticals are manufactured in a known manner.
• auxiliaries come e.g. those in question which are recommended or indicated in the following literature as auxiliary substances for pharmacy, cosmetics and related fields: Ullmanns Encyklopadie der Technische Chemie, Volume 4 (1953), pages 1 to 39; Journal of Pharmaceutical Sciences, Volume 52 (1 963), page 91 8 ff., H. v. Czetsch-Lindenwald, auxiliaries for pharmacy and neighboring areas; Pharm. Ind., No. 2 (1 961), page 72 u. ff .: Dr. H. P. Fiedler, Lexicon of auxiliaries for pharmacy, cosmetics and related areas, Cantor KG, Aulendorf in WORK 1 971.
• the compounds can be administered orally or parenterally, for example intraperitoneally, intramuscularly, subcutaneously or percutaneously.
• the connections can also be implanted into the tissue.
• the dosage units can include a pharmaceutically acceptable carrier such as e.g. Contain starch, sugar, sorbitol, gelatin, lubricant, silica, talc, etc.
• a pharmaceutically acceptable carrier such as e.g. Contain starch, sugar, sorbitol, gelatin, lubricant, silica, talc, etc.
• the active ingredients can be dissolved or suspended in a physiologically acceptable diluent.
• Oils with or without the addition of a solubilizer, a surface-active agent, a suspending or emulsifying agent are very often used as diluents. Examples of oils used are olive oil, peanut oil, cottonseed oil, soybean oil, castor oil and sesame oil.
• the compounds can also be used in the form of a depot injection or an implant preparation, which can be formulated in such a way that a delayed release of the active substance is made possible.
• Implants can be used as inert materials e.g. contain biodegradable polymers or synthetic silicones such as Silicone rubber.
• the active ingredients can also be used percutaneously, e.g. to be worked into a plaster.
• intravaginal systems loaded with active (eg, vaginal rings) or intrauterine systems (eg, pessaries, coils, ents, Mirena ®) for local administration
• active eg, vaginal rings
• intrauterine systems eg, pessaries, coils, ents, Mirena ®
• various polymers are suitable, such as silicone polymers, Ethylenvin ⁇ lacetat, polyethylene or polypropylene.
• the compounds can also be formulated as cyclodextrin clathrates.
• the compounds are reacted with a, ⁇ - or J ⁇ -cyclodextrin or derivatives thereof (PCT / EP95 / 02656).
• the active ingredients can also be encapsulated with liposomes.
• Figure 1 The effect of test substances on the expression of a NF / cb-controlled reporter gene in an ER ⁇ -positive cell.
• Figure 2 The effect of test substances on the expression of a NF / cb-controlled reporter gene in an ERß-positive cell.
• Figures 3 and 4 The effect of test substances or combinations of
• MVLN cells The antiestrogenic effect of SERMs is determined by transactivation test in MVLN cells. These are MCF-7 breast cancer cells which have been stably transfected with a vitellogenin ERE luciferase reporter gene (Demirpence et al. (1993), J. Steroid Biochem. Mo. Biol. 46, 355-364).
• the binding affinity of the new selective estrogens (ERß ligands) and SERMs was tested in competition experiments using 3H-estradiol as a ligand on estrogen receptor preparations of rat prostate and rat uterus.
• the preparation of the prostatacytosol and the estrogen receptor test with the prostatacytosol was carried out as described by Testas et al. (1 981), performed (Testas J. et al. (1 981), Endocrinology 109, 1 287-1 289).
• the ERß ligands claimed in the present patent for use in the combination preparation have a higher binding affinity for estrogen receptor from rat prostate than from rat uterus. It is assumed that ERß outweighs ER ⁇ in the prostate rat and ER ⁇ outweighs ERß in rat uterus. In agreement with this we find that the ratio of the binding to the prostate and uterine receptor qualitatively with the quotient of the relative binding affinity (RBA) to human ERß and ER ⁇ from rat (after Kuiper et al. (1 996), Endocrinology 1 38, 863- 870) match.
• RBA relative binding affinity
• the reporter gene assay was carried out in U2-OS human osteosarcoma cells as described (Fritzemeier, Hegele-Hartung (1 999), Handbook of Pharmacol., Oettel, Schillinger ed. 135/11, 21, 1-94).
• the cells were transiently transfected with a reporter gene that was under the control of a promoter containing an NF / cb binding site.
• the cells were transfected with expression vectors for hER ⁇ and / or hERß.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Endocrinology (AREA)
• Physical Education & Sports Medicine (AREA)
• Rheumatology (AREA)
• Diabetes (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Cardiology (AREA)
• Urology & Nephrology (AREA)
• Immunology (AREA)
• Heart & Thoracic Surgery (AREA)
• Psychiatry (AREA)
• Anesthesiology (AREA)
• Pain & Pain Management (AREA)
• Vascular Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Reproductive Health (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7652064

Family Applications (1)

Country Status (6)

Families Citing this family (8)

Family Cites Families (13)

• 2000
  • 2000-08-10 DE DE10039199A patent/DE10039199A1/de not_active Ceased
• 2001
  • 2001-08-03 EP EP01974107A patent/EP1307229A1/de not_active Withdrawn
  • 2001-08-03 JP JP2002517099A patent/JP2004505929A/ja active Pending
  • 2001-08-03 WO PCT/EP2001/009008 patent/WO2002011765A1/de active Application Filing
  • 2001-08-03 US US10/344,161 patent/US20040053898A1/en not_active Abandoned
  • 2001-08-03 AU AU2001293720A patent/AU2001293720A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events